<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>smith</title>
    <link rel="stylesheet" href="nobles.css">

</head>

<body>

    <body>
        <div class="main-header">
            <h1 class="heading">MARY L.TERY </h1>
        </div>
        <div class="container">
            <div class="main content">
                <p>Dr. Mary L. Terry is a prominent researcher known for her work in pediatric oncology and cancer
                    genetics. She earned her medical degree from Duke University School of Medicine and completed her
                    pediatric residency at the University of North Carolina at Chapel Hill.
                    Dr. Terry's research has focused on understanding the genetic basis of pediatric cancers. In
                    particular, she has studied cancer predisposition syndromes, which are genetic conditions that
                    increase a person's risk of developing certain types of cancer.

                    By identifying specific genetic mutations associated with childhood cancer, Dr. Terry's work has
                    improved risk assessment for children with certain predispositions. This knowledge has allowed for
                    more targeted screening and surveillance, enabling earlier detection and intervention when
                    necessary.

                    Furthermore, understanding the genetic underpinnings of pediatric cancers has led to the development
                    of targeted therapies that can specifically address the molecular abnormalities driving the cancer's
                    growth. This personalized medicine approach has shown promise in improving treatment outcomes for
                    children with these specific genetic subtypes of cancer.

                    Dr. Terry's dedication to unraveling the complexities of pediatric cancer genetics has advanced the
                    field of precision medicine and contributed to better-informed treatment decisions for young
                    patients.

                    Dr. Elizabeth J. Perlman:
                    Dr. Elizabeth J. Perlman is a pediatric pathologist who has made significant contributions to the
                    classification and understanding of pediatric kidney tumors, with a particular focus on Wilms tumor.
                    Wilms tumor is the most common kidney cancer in children, and its diagnosis and treatment have been
                    significantly impacted by Dr. Perlman's research. She obtained her medical degree from Northwestern
                    University Medical School and completed her pathology residency at the University of Chicago
                    Hospitals.

                    Through her work as a pathologist, Dr. Perlman identified specific features and molecular markers
                    that allowed for more accurate and reliable classification of Wilms tumors into distinct subtypes.
                    This classification system has important implications for treatment decisions, as some subtypes of
                    Wilms tumor are associated with different outcomes and may require different treatment approaches.

                    Dr. Perlman's research has also provided insights into the genetic basis of Wilms tumor, leading to
                    a better understanding of the molecular pathways involved in tumor development. This knowledge has
                    paved the way for the development of targeted therapies that hold promise for improving outcomes in
                    certain cases of Wilms tumor.

                    In addition to her research contributions, Dr. Perlman has been involved in collaborative efforts to
                    standardize pathology reporting and improve diagnostic accuracy for pediatric kidney tumors. Her
                    dedication to pediatric pathology and her commitment to improving patient care have earned her
                    recognition as a leading figure in the field.

                    In conclusion, each of these exceptional individuals has made significant contributions to the field
                    of childhood cancer research, pioneering new treatments, improving diagnostics, and advancing our
                    understanding of pediatric cancers. Through their dedication and groundbreaking work, they have
                    brought hope and progress to countless children and their families, inspiring ongoing research and
                    advancements in pediatric oncology. Their legacies continue to shape the landscape of childhood
                    cancer research and treatment, making a lasting impact on the lives of young patients worldwide.</p>
                </p>
            </div class="img-divs">
            <img class=" img-margin" src="photos3/MARY.jfif" width="400px" height="200px">
        </div>


    </body>

</html>